Diagnostic Uses of Pax5 Immunohistochemistry
- 1 September 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 14 (5) , 323-334
- https://doi.org/10.1097/pap.0b013e3180ca8a49
Abstract
Pax5, or B-cell-specific activator protein, is a nuclear protein in the paired-box containing (PAX) family of transcription factors involved in control of organ development and tissue differentiation. Pax5 is mostly expressed in B lymphocytes and B-cell lymphomas, although recent data have shown expression in the developing central nervous system, some neuroendocrine tumors, and occasional myeloid leukemias. Pax5 immunohistochemistry shows robust nuclear staining, and has become a valuable tool in the diagnosis and subclassification of lymphomas. Pax5 staining is positive in most Hodgkin and B-cell non-Hodgkin lymphomas, and also precursor B-cell lymphoblastic neoplasms. Plasma cell neoplasms, multiple myeloma, and plasmablastic lymphomas typically are negative. T-cell lymphomas are, to date, consistently negative. Recently, Pax5 expression has been described in the majority of small cell carcinomas and Merkel cell carcinomas. Rare cases of Pax5 expression in other carcinomas have been reported. With these exceptions, Pax5 immunohistochemistry is fairly specific for B-cell lineage and is a valuable addition to the armamentarium of markers available for lymphoma subtyping.Keywords
This publication has 40 references indexed in Scilit:
- Pax-5 Expression in Nonhematopoietic TissuesAmerican Journal of Clinical Pathology, 2006
- Lineage Determination of CD20– B-Cell NeoplasmsAmerican Journal of Clinical Pathology, 2006
- Expression of B Cell–Specific Activator Protein/PAX5 in Acute Myeloid Leukemia With t(8;21)(q22;q22)American Journal of Clinical Pathology, 2006
- Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarraysLaboratory Investigation, 2006
- PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B‐NHL with complex chromosomal rearrangementsGenes, Chromosomes and Cancer, 2005
- Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphomaLaboratory Investigation, 2004
- Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarrayLaboratory Investigation, 2004
- The B-Cell Transcription Factors BSAP, Oct-2, and BOB.1 and the Pan–B-Cell Markers CD20, CD22, and CD79a Are Useful in the Differential Diagnosis of Classic Hodgkin LymphomaAmerican Journal of Clinical Pathology, 2003
- Nodal Marginal Zone Lymphoma: A Heterogeneous TumorThe American Journal of Surgical Pathology, 2003
- The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de‐differentiationBJU International, 1999